Gundars Goldsteins

Pharmatory Oy provides pharmaceutical ingredients and related services. It specializes in route scouting, process research and development, scale-up and cGMP manufacturing of key intermediates and active pharmaceutical ingredients (APIs) with focus on quality operation and timely delivery. The company was founded in 2001 and is headquartered in Oulu, Finland.

Rokote Laboratories Finland Oy is a Finnish vaccine development company established in 2020 with premises located in Kuopio and Helsinki. The private company aims to consolidate the use of new vaccine technology and is currently developing a second-generation coronavirus vaccine. The company's focus is on developing a COVID-19 vaccine, with clinical trials set to begin this year.

Laurantis Pharma Oy engages in the development of pharmaceutical products. The company was founded in July 2008 and is headquartered in Turku, Finland.

Aplagon Oy provides pharmaceutical discovery and development services. It develops locally acting antithrombotic products (APACs). The company was founded by Riitta Lassila and Yrjo Sakari Lassila in 2009 and is headquartered in Helsinki, Finland.

Medtentia International Ltd. Oy is a holding company that develops solutions for mitral valve repair based on its proprietary helix ring concept. It is a medical technology company that creates solutions for cardiac interventions. It provides proprietary, helix-shaped products to address the unmet need in cardiac surgery. The company was founded by Dan Mogren and Olli U. Keränen in 2002 by Olli Keränen and is headquartered in Espoo, Finland.

Onbone Oy develops medical casting and splinting materials for use in the fields of orthopaedics, traumatology and occupational therapy. The company was founded by Petro Antero Kirmo Lahtinen, Antti Pärssinen, Jari Juhani Salo, Matti Eino Olavi Vaheri, and Karri Airola on November 18, 2008 and is headquartered in Oulu, Finland.

Teitur Trophics ApS develops novel treatments. The company is based in Aarhus, Denmark. The Danish company was founded by Simon Mølgaard, Mathias Kaas Ollendorff, Anders Dalby, Simon Glerup. Simon Mølgaard has been the CEO since incorporation.

Inveni Capital Oy is a venture capital investment firm with offices in Helsinki and Munich. The Finnish-German firm was founded in 2007. Their investors include the Finnish Industry Investment Ltd. as largest single investor, along with other private investors and funds as well as the University of Helsinki.

Bone Index Finland Oy develops solutions for osteoporosis diagnostics. The firm specializes in the development of measuring devices for osteoporosis screening and diagnosis. The company was founded by Ossi Riekkinen and Janne Karjalainen in 2011 and is headquartered in Kuopio, Finland.

Part of University of Helsinki, Helsinki Innovation Services Ltd. is a company that provides business and innovation-related consulting services. The company is based in Helsinki, Finland.

Innovestor Ventures Oy is a venture capital firm, a subsidiary of Innovestor Oy founded in 2014. The firm is headquartered in Helsinki, Finland.

Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020.

Innovestor Oy is a venture and growth equity firm headquartered in Helsinki, Finland. The firm was founded by Tommi Äijälä and Antti Parviainen in 2014.

Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020.

Charles River Discovery Research Services Finland Oy provides non-clinical central nervous system services to the pharmaceutical and biotechnology industries. The company was founded in 1998 and is located in Kuopio, Finland.

Osuuskunta KPY operates as a long-term investor. It also rents office space and invests in securities. The company was founded in 1883 and is headquartered in Kuopio, Finland.

Tarrex Biopharma Ltd develops pharmaceuticals. The company was founded by Kanyin E.Zhang and Xiaokun Zhang and is headquartered in Xiamen, China.